|
| 37406106 | Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer. | Clin Cancer Res | 2023 |
| 35046520 | Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. | Br J Cancer | 2022 |
| 35704974 | Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. | Eur J Cancer | 2022 |
| 34095713 | Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. | JCO Precis Oncol | 2021 |
| 33902046 | Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort. | Oncology | 2021 |
| 34994593 | Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer. | JCO Precis Oncol | 2021 |
| 31412004 | Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. | Eur Urol Oncol | 2020 |
| 32086345 | MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer. | Clin Cancer Res | 2020 |
| 31806627 | Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i>-Mutant Metastatic Breast Cancer. | Cancer Discov | 2020 |
| 32102950 | Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer. | Clin Cancer Res | 2020 |
| 32864625 | Alterations in <i>PTEN</i> and <i>ESR1</i> promote clinical resistance to alpelisib plus aromatase inhibitors. | Nat Cancer | 2020 |
| 32477464 | Blood-based next-generation sequencing analysis of neuroendocrine neoplasms. | Oncotarget | 2020 |
| 32437664 | First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. | Lancet Oncol | 2020 |
| 32540409 | Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. | J Thorac Oncol | 2020 |
| 32297439 | Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer. | Oncologist | 2020 |
| 30664990 | Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC. | J Thorac Oncol | 2019 |
| 35100741 | Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers. | JCO Precis Oncol | 2019 |
| 32923867 | Genomic Profiling for <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i>, Microsatellite Instability, and Mismatch Repair Deficiency Among Patients With Metastatic Colon Cancer. | JCO Precis Oncol | 2019 |
| 31533235 | <i>BRAF</i> Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. | Cancers (Basel) | 2019 |
| 31442103 | Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10. | J Clin Oncol | 2019 |
| 31358542 | Treatment with Next-Generation ALK Inhibitors Fuels Plasma <i>ALK</i> Mutation Diversity. | Clin Cancer Res | 2019 |
| 31427281 | Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma. | Clin Cancer Res | 2019 |
| 31367539 | Therapeutic outcomes in non-small cell lung cancer with <i>BRAF</i> mutations: a single institution, retrospective cohort study. | Transl Lung Cancer Res | 2019 |
| 31632838 | Identification of osimertinib-resistant <i>EGFR</i> L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort. | Exp Hematol Oncol | 2019 |
| 31392055 | Feasibility of circulating tumor DNA testing in hepatocellular carcinoma. | J Gastrointest Oncol | 2019 |
| 30808777 | Plasma HER2 (<i>ERBB2</i>) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. | Clin Cancer Res | 2019 |
| 30770491 | Correction: <i>PIK3CA</i> C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3Kα Inhibitors. | Clin Cancer Res | 2019 |
| 30737217 | Correction: An Acquired <i>HER2</i> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant-Driven Breast Cancer. | Cancer Discov | 2019 |
| 30914635 | Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. | Nat Commun | 2019 |
| 30463996 | <i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i>-Amplified Esophagogastric Cancer. | Cancer Discov | 2019 |
| 30350351 | Fine mapping of 14q13 reveals novel variants associated with different histological subtypes of papillary thyroid carcinoma. | Int J Cancer | 2019 |
| 30314968 | Combined Blockade of Activating <i>ERBB2</i> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. | Clin Cancer Res | 2019 |
| 30620391 | Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer. | Cancer | 2019 |
| 29236940 | Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer. | Ann Oncol | 2018 |
| 35135131 | Use of Low-Frequency Driver Mutations Detected by Cell-Free Circulating Tumor DNA to Guide Targeted Therapy in Non-Small-Cell Lung Cancer: A Multicenter Case Series. | JCO Precis Oncol | 2018 |
| 30211110 | Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer. | Front Oncol | 2018 |
| 30072474 | Amplification of Wild-type <i>KRAS</i> Imparts Resistance to Crizotinib in <i>MET</i> Exon 14 Mutant Non-Small Cell Lung Cancer. | Clin Cancer Res | 2018 |
| 29990497 | Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. | Cancer Cell | 2018 |
| 30123863 | Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer. | JCO Precis Oncol | 2018 |
| 29903880 | Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. | Cancer Discov | 2018 |
| 30257958 | Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion. | Cancer Discov | 2018 |
| 31501807 | Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in <i>BRCA2</i>-Associated Prostate Cancer Resulting From Biallelic <i>BRCA2</i> Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations. | JCO Precis Oncol | 2018 |
| 30368414 | Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC. | J Thorac Oncol | 2018 |
| 30339520 | Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. | J Clin Oncol | 2018 |
| 29449271 | Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i>-Amplified Gastroesophageal Adenocarcinoma. | Cancer Discov | 2018 |
| 29776953 | The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients. | Clin Cancer Res | 2018 |
| 29691297 | Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies. | Clin Cancer Res | 2018 |
| 29517810 | Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. | Cancer | 2018 |
| 29559559 | Anaplastic Lymphoma Kinase Mutation (<i>ALK</i> F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. | Clin Cancer Res | 2018 |
| 29284706 | <i>PIK3CA</i> C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K<b>α</b> Inhibitors. | Clin Cancer Res | 2018 |